Orphazyme A/S (ORPHY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Orphazyme A/S (ORPHY) trades at $0.03. Orphazyme A/S is a Danish biopharmaceutical company focused on developing therapies for neurodegenerative rare diseases. Their lead candidate, Arimoclomol, targets diseases like Niemann-Pick disease type C and Amyotrophic Lateral Sclerosis. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for ORPHY: ORPHY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ORPHY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ORPHY: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Orphazyme A/S (ORPHY) Healthcare & Pipeline Overview
Orphazyme A/S, a biopharmaceutical company based in Denmark, specializes in developing therapies for neurodegenerative rare diseases, leveraging heat shock proteins to combat misfolded proteins. Their lead candidate, Arimoclomol, is in clinical trials for Niemann-Pick disease type C and Amyotrophic Lateral Sclerosis, positioning them in the competitive biotechnology landscape.
What Is the Investment Thesis for ORPHY?
Orphazyme A/S presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on rare neurodegenerative diseases, particularly with its lead candidate Arimoclomol, offers potential for significant returns if clinical trials are successful and regulatory approvals are obtained. However, the company's negative P/E ratio of -79.98 reflects its current lack of profitability and reliance on future success. Upcoming catalysts include continued clinical trial progress for Arimoclomol in various indications. The primary value driver is the potential for Arimoclomol to become a first-in-class treatment for diseases with limited or no existing therapeutic options. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding to support ongoing research and development.
Based on FMP financials and quantitative analysis
ORPHY Key Highlights
Orphazyme A/S specializes in developing therapies for neurodegenerative rare diseases.
- The company's lead candidate, Arimoclomol, is in clinical development for Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis.
- Orphazyme A/S leverages heat shock proteins to combat misfolded proteins, aggregated proteins, and dysfunctional lysosomes.
- The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
- Orphazyme A/S has a P/E ratio of -79.98, reflecting its current lack of profitability.
Who Are ORPHY's Competitors?
ORPHY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ORPHY's Key Strengths?
Focus on a specific therapeutic area (neurodegenerative rare diseases).
- Proprietary technology platform based on heat shock proteins.
- Lead candidate (Arimoclomol) in clinical development for multiple indications.
- Experienced management team.
What Are ORPHY's Weaknesses?
Limited financial resources.
- Dependence on the success of Arimoclomol.
- Lack of commercialized products.
- Small number of employees.
What Could Drive ORPHY Stock Higher?
Continued clinical trial progress for Arimoclomol in Niemann-Pick disease type C.
- Clinical trial results for Arimoclomol in Amyotrophic Lateral Sclerosis.
- Potential regulatory submissions for Arimoclomol in various indications.
- Research and development efforts to expand the pipeline with new drug candidates.
What Are the Key Risks for ORPHY?
Negative return on equity (-4.7%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures for Arimoclomol.
- Regulatory hurdles and delays in approval processes.
- Competition from other companies developing therapies for neurodegenerative diseases.
- Need for additional funding to support ongoing research and development.
- Dependence on the success of Arimoclomol.
What Are the Growth Opportunities for ORPHY?
- Growth opportunity 1: Successful clinical trials and regulatory approval for Arimoclomol in Niemann-Pick disease type C (NPC) represent a significant growth opportunity. The NPC market, while relatively small, has a high unmet need for effective therapies. Positive trial results could lead to accelerated approval pathways and orphan drug designation, providing market exclusivity and premium pricing. The timeline for potential approval is dependent on ongoing clinical trial data and regulatory review, with potential for market entry within the next 2-3 years.
- Growth opportunity 2: Expanding the application of Arimoclomol to other neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS) and Inclusion Body Myositis (IBM), offers substantial growth potential. The ALS and IBM markets are larger than the NPC market, but also more competitive. Positive clinical trial results in these indications could significantly increase the market opportunity for Arimoclomol. The timeline for these indications is dependent on ongoing clinical trials, with potential for market entry in the next 3-5 years.
- Growth opportunity 3: Strategic partnerships with larger pharmaceutical companies could provide Orphazyme A/S with access to additional funding, resources, and expertise to accelerate the development and commercialization of Arimoclomol. Collaborations could also expand the company's geographic reach and market access. The timeline for potential partnerships is uncertain, but could occur at any point in the near future.
- Growth opportunity 4: Further research and development into novel heat shock protein-based therapies could lead to the discovery of new drug candidates and expand Orphazyme A/S's pipeline. This would diversify the company's risk and create new growth opportunities beyond Arimoclomol. The timeline for new drug discovery is uncertain, but could yield results in the long term.
- Growth opportunity 5: Leveraging the company's expertise in heat shock proteins to develop diagnostic tools for neurodegenerative diseases could create a new revenue stream and complement its therapeutic development efforts. Diagnostic tools could help identify patients who are most likely to benefit from Arimoclomol and other therapies. The timeline for developing diagnostic tools is uncertain, but could be a mid-term growth opportunity.
What Are ORPHY's Competitive Advantages?
- Proprietary technology platform based on heat shock proteins.
- Patent protection for Arimoclomol and related therapies.
- Orphan drug designation for certain indications, providing market exclusivity.
- Expertise in developing therapies for rare diseases.
What Does ORPHY Do?
Orphazyme A/S, established in 2009 and headquartered in Copenhagen, Denmark, is a biopharmaceutical company dedicated to developing novel therapies for the treatment of neurodegenerative rare diseases. The company's core focus lies in harnessing the cell-protective properties of the heat shock response, a mechanism that shields cells from the harmful accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. This approach aims to address the underlying causes of several debilitating conditions. Orphazyme's lead candidate, Arimoclomol, is currently in clinical development for a range of diseases, including Niemann-Pick disease type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM). Arimoclomol is designed to amplify the heat shock response, thereby enhancing the cell's ability to clear toxic protein aggregates and maintain cellular function. The company's research and development efforts are centered on advancing Arimoclomol through clinical trials and seeking regulatory approvals to bring this potential therapy to patients in need. Orphazyme operates with a team of 62 employees, focused on research, development, and clinical operations.
What Products and Services Does ORPHY Offer?
- Develop therapies for neurodegenerative rare diseases.
- Focus on heat shock proteins to protect cells from misfolded proteins.
- Offer Arimoclomol as a lead candidate in clinical development.
- Target diseases including Niemann-Pick disease type C.
- Target diseases including Amyotrophic Lateral Sclerosis.
- Target diseases including Inclusion Body Myositis.
How Does ORPHY Make Money?
- Develop and patent novel therapies for rare diseases.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA and EMA.
- Potentially commercialize therapies directly or through partnerships.
What Industry Does ORPHY Operate In?
Orphazyme A/S operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The company focuses on the rare disease market, which often offers orphan drug status and expedited regulatory pathways. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms also targeting neurodegenerative diseases. The industry is driven by increasing demand for innovative treatments and advancements in understanding disease mechanisms.
Who Are ORPHY's Key Customers?
- Patients suffering from neurodegenerative rare diseases.
- Healthcare providers who treat these patients.
- Hospitals and clinics that administer the therapies.
- Potential pharmaceutical partners for commercialization.
Company Profile
Orphazyme A/S operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Copenhagen, DK. The company is led by CEO Anders Fink Vadsholt MBA.
Key Financial Metrics
Return on equity for Orphazyme A/S stands at -4.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 13.90 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.5%, the inverse of the P/E and a quick read on earnings relative to price.
ORPHY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on a specific therapeutic area (neurodegenerative rare diseases).
- Proprietary technology platform based on heat shock proteins.
- Lead candidate (Arimoclomol) in clinical development for multiple indications.
- Experienced management team.
Bear Case
- Limited financial resources.
- Dependence on the success of Arimoclomol.
- Lack of commercialized products.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ORPHY Latest News
No recent news available for ORPHY.
ORPHY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ORPHY.
Price Targets
Wall Street price target analysis for ORPHY.
ORPHY MoonshotScore
What does this score mean?
The MoonshotScore rates ORPHY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Anders Fink Vadsholt MBA
CEO
Anders Fink Vadsholt is the CEO of Orphazyme A/S. He brings extensive management experience to the company, overseeing a team of 62 employees. His MBA provides a strong foundation in business strategy and leadership. Prior to joining Orphazyme, Vadsholt held various leadership positions in the pharmaceutical and biotechnology industries, focusing on commercialization and strategic development. His background encompasses a range of therapeutic areas, with a growing emphasis on rare diseases.
Track Record: Since joining Orphazyme A/S, Anders Fink Vadsholt has focused on advancing the clinical development of Arimoclomol and securing funding for ongoing research and development. Key milestones under his leadership include initiating and progressing clinical trials for Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. He has also worked to establish strategic partnerships to support the company's growth.
Orphazyme A/S ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. ORPHY, as an ADR, allows U.S. investors to trade shares of Orphazyme A/S, a Danish company, on the OTC market without the complexities of cross-border transactions. The depositary bank handles currency conversions and other administrative tasks.
- Home Market Ticker: Nasdaq Copenhagen, Denmark
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ORPH
ORPHY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. Companies in this tier do not have to meet minimum financial standards.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Higher risk of fraud or scams.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Check for any red flags or warning signs.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- The company was incorporated in 2009.
- The company has a lead candidate (Arimoclomol) in clinical development.
- The company has a team of 62 employees.
- The company is headquartered in Copenhagen, Denmark.
ORPHY Healthcare Stock FAQ
What does Orphazyme A/S do?
Orphazyme A/S is a biopharmaceutical company focused on developing therapies for neurodegenerative rare diseases. The company's core technology revolves around heat shock proteins, which protect cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Their lead candidate, Arimoclomol, is in clinical development for diseases such as Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis.
What do analysts say about ORPHY stock?
Analyst coverage of ORPHY stock is unknown, given its OTC listing and limited financial disclosure. Key valuation metrics, such as revenue growth and profitability, are difficult to assess due to the lack of available data. Growth considerations center on the potential success of Arimoclomol in clinical trials and the company's ability to secure regulatory approvals.
What are the main risks for ORPHY?
The main risks for ORPHY include clinical trial failures, regulatory hurdles, and the need for additional funding. As a biopharmaceutical company, Orphazyme A/S faces the inherent risk that its lead candidate, Arimoclomol, may not demonstrate sufficient efficacy or safety in clinical trials.
What are the key factors to evaluate for ORPHY?
Evaluate ORPHY on fundamentals, analyst consensus, and risk factors. Orphazyme A/S presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does ORPHY data refresh on this page?
ORPHY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ORPHY's recent stock price performance?
Orphazyme A/S (ORPHY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a specific therapeutic area (neurodegenerative rare diseases). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ORPHY overvalued or undervalued right now?
Orphazyme A/S (ORPHY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ORPHY before investing?
Before investing in Orphazyme A/S (ORPHY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- OTC stocks carry higher risks than exchange-listed stocks.